News
![Why Shares of Ardelyx Were Down Wednesday: https://g.foolcdn.com/editorial/images/750658/adaptimmune.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0tzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--001d15434257a989141f4916d475b4beeb36f193/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/adaptimmune.jpg?locale=us)
Why Shares of Ardelyx Were Down Wednesday
Shares of Ardelyx (NASDAQ: ARDX) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this
![3 Reasons to Buy Abbott Laboratories Stock: https://g.foolcdn.com/editorial/images/749549/doctor-and-patient-in-a-hospital-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMytzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--59f35c5f735fa8d346b2970b6d5809ee1298e75c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-in-a-hospital-room.jpg?locale=us)
3 Reasons to Buy Abbott Laboratories Stock
Medical device giant Abbott Laboratories (NYSE: ABT) hasn't performed well in the past year. The company has had to deal with several issues that affected its results and its public image, notably
![AT&T Stock Offers a Magnificent Dividend Yield -- but These 2 Key Metrics Are Flashing Warning Signs: https://g.foolcdn.com/editorial/images/750229/t-roic-wacc-over-time.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0tyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a608096a0d60073203a1a10792c7f9ada3fc7e02/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/t-roic-wacc-over-time.png?locale=us)
AT&T Stock Offers a Magnificent Dividend Yield -- but These 2 Key Metrics Are Flashing Warning Signs
Despite strong gains for the broader market this year, AT&T (NYSE: T) stock continues to struggle. The company's share price is down nearly 19% so far in 2023. With the stock trading at low earnings
![Down 45%, Is Intellia a Buy?: https://g.foolcdn.com/editorial/images/750266/gettyimages-903626078.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFNyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aec0b7fff346e6b3ca4ea7cc14d2e3eb082a06d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-903626078.jpg?locale=us)
Down 45%, Is Intellia a Buy?
Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron
![This Cathie Wood Stock Is Poised to Double, Says Wall Street: https://g.foolcdn.com/editorial/images/749217/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0NyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--23114cffa7404f153c8cd56bdaab8e8eaa6b1b87/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=us)
This Cathie Wood Stock Is Poised to Double, Says Wall Street
Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in
![Why Shares of Scilex Are Up Monday: https://g.foolcdn.com/editorial/images/750336/a-scientist-uses-a-pipette-to-work-with-medical-samples.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTZwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3c8d2169da0c8a2094f1a43210f42c813979a3ff/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-scientist-uses-a-pipette-to-work-with-medical-samples.jpg?locale=us)
Why Shares of Scilex Are Up Monday
Shares of Scilex Holdings (NASDAQ: SCLX) were up around 14% as of 2:30 p.m. ET on Monday. The healthcare stock is still down more than 55% this year.
Scilex makes non-opioid pain management products
![Why Shares of Tango Therapeutics Are Dropping Monday: https://g.foolcdn.com/editorial/images/750293/healthcare-lab-treatment-research-scientist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzZwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0be1d857818792175460c2b036320acffddbecbc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist.jpg?locale=us)
Why Shares of Tango Therapeutics Are Dropping Monday
Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.
Tango is a clinical-stage biotech that focuses on
![EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelB3SXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--521237387ec8207326f44117d145b81c1391bc28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_color_high_res.jpg?locale=us)
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
![1 Reason to Buy AT&T Stock, and 1 Reason to Avoid: https://g.foolcdn.com/editorial/images/750145/telecom-worker-woman-industrials-5g-tech-8.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3VvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--020c7ea0207afccf66943f281cc36581cf73467d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-worker-woman-industrials-5g-tech-8.jpg?locale=us)
1 Reason to Buy AT&T Stock, and 1 Reason to Avoid
The stock market has rendered its verdict on AT&T (NYSE: T) stock this year. While the S&P 500 is up around 10% year-to-date, shares of the telecom giant have tumbled roughly 20%.
There are some
![Cathie Wood Warns About a Hard Landing for the Economy, but Thinks Artificial Intelligence (AI) Could Come to the Rescue: https://g.foolcdn.com/editorial/images/750062/ai-artificial-intelligence-in-circle-on-keyboard.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTJvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--970e55bfdf4967913849fefba377b3caa8fd5b4e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ai-artificial-intelligence-in-circle-on-keyboard.jpg?locale=us)
Cathie Wood Warns About a Hard Landing for the Economy, but Thinks Artificial Intelligence (AI) Could Come to the Rescue
Cathie Wood manages net assets of around $12 billion in her Ark Invest exchange-traded funds (ETFs). It's part of her job to keep close tabs on macroeconomic trends while also focusing on major
![Is Editas Stock a Buy Now?: https://g.foolcdn.com/editorial/images/749818/dna-genetic-sequencing-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODJvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5502b3a7874d6d346f904b1f5b61039eac050003/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech.jpg?locale=us)
Is Editas Stock a Buy Now?
Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at
![3 No-Brainer Growth Stocks to Buy in October: https://g.foolcdn.com/editorial/images/749965/hands-behind-head-young-man.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk9vYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--011c5adcdfe2a6954557179b2ebdd5dc68002f44/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/hands-behind-head-young-man.jpg?locale=us)
3 No-Brainer Growth Stocks to Buy in October
Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.
Three Motley Fool contributors think they've picked some stocks
![This Could be Novavax's Big Opportunity: https://g.foolcdn.com/editorial/images/749944/gettyimages-1266812068.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNStvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fabe253bb891d52c99054ddcf6044b309ef458c0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1266812068.jpg?locale=us)
This Could be Novavax's Big Opportunity
Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the
![Why AT&T Stock Fell Today: https://g.foolcdn.com/editorial/images/750135/divest-divestment-sri-esg-sustainability-socially-conscious.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3lvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--61e6450fd72978d76f2807598b5bba7e3af4d2a4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/divest-divestment-sri-esg-sustainability-socially-conscious.jpg?locale=us)
Why AT&T Stock Fell Today
Shares of AT&T (NYSE: T) fell as much as 6% early Friday, then settled to close down around 2.7% following a report that the company is weighing whether to divest its stake in DirecTV next year.
![Should You Load Up On This 1 Dividend Stock?: https://g.foolcdn.com/editorial/images/749688/doctor-and-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenVvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2e5660301e5e7cd4704d26b29fca5da38c71211e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-talking.jpg?locale=us)
Should You Load Up On This 1 Dividend Stock?
There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a
![Better Growth Stock: Novo Nordisk vs. Pfizer: https://g.foolcdn.com/editorial/images/749634/two-scientists-reviewing-a-sample-in-a-tube.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekNvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3aa654c01be279978110169520efb37e223e4637/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-scientists-reviewing-a-sample-in-a-tube.jpg?locale=us)
Better Growth Stock: Novo Nordisk vs. Pfizer
Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID
![2 Reasons to Buy AT&T Stock, and 2 Reasons to Avoid It: https://g.foolcdn.com/editorial/images/749640/person-taking-selfie-with-child.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1duYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--89a6277a51ac2664b1db04c3fd1662763bcd806a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-taking-selfie-with-child.jpg?locale=us)
2 Reasons to Buy AT&T Stock, and 2 Reasons to Avoid It
For dividend investors, AT&T (NYSE: T) stock may seem like one of the best options simply because of its tantalizing 7.4% dividend yield. However, there is more to a company than just how much of a
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Why Coherus BioSciences Stock Popped Today: https://g.foolcdn.com/editorial/images/749999/medicine-pills-fda-approval-stamp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2luYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a5a96bdd501fa37102426971eaac4e007a1cfdc1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medicine-pills-fda-approval-stamp.jpg?locale=us)
Why Coherus BioSciences Stock Popped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) rose 9.4% on Thursday after the biotech resubmitted a biologic license application (BLA) supplement for a key product to the U.S. Food and Drug
![Why Shares of uniQure Are Up Thursday: https://g.foolcdn.com/editorial/images/749981/scientists-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGVuYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5afc9ab88616914060f1ea2227cd699e71cdb5b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-in-a-lab.jpg?locale=us)
Why Shares of uniQure Are Up Thursday
Shares of uniQure (NASDAQ: QURE) were up more than 8% as of 1 p.m. after rising as much as 14% earlier in the day. So far this year, the biotech stock is down more than 70%.
The gene-editing therapy
![This Market-Beating Stock Just Gave Investors More Reasons to Invest: https://g.foolcdn.com/editorial/images/749201/patient-sitting-on-hospital-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2luYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cea74d6ab0ab8307b7002efe7b178757592a11d3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-sitting-on-hospital-bed.jpg?locale=us)
This Market-Beating Stock Just Gave Investors More Reasons to Invest
Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite
EQS-Adhoc: Biotest AG: Increase of the EBIT guidance
EQS-Adhoc: Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB': http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)